Here are what the editors at HealthDay consider to be the most important developments in Pediatrics for January 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Rising Temps May Up Burden of Congenital Heart Disease in U.S.
THURSDAY, Jan. 31, 2019 (HealthDay News) — Projected increases in maternal heat exposure may result in increased congenital heart defect (CHD) burden, according to a study published online Jan. 30 in the Journal of the American Heart Association.
FDA Approves First Generic Version of Advair for Asthma, COPD
THURSDAY, Jan. 31, 2019 (HealthDay News) — The first generic form of the Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhaler has been approved by the U.S. Food and Drug Administration.
More High-Value Care Associated With Receipt of Primary Care
THURSDAY, Jan. 31, 2019 (HealthDay News) — Receipt of primary care is associated with significantly more high-value care, slightly more low-value care, and a better health care experience, according to a study published online Jan. 28 in JAMA Internal Medicine.
FDA Receives an ‘F’ in Tobacco Prevention Report Card
WEDNESDAY, Jan. 30, 2019 (HealthDay News) — The U.S. Food and Drug Administration was given an “F” in a new American Lung Association report card evaluating tobacco prevention programs.
Expanded Recall Announced for Ibuprofen Oral Suspension Drops
WEDNESDAY, Jan. 30, 2019 (HealthDay News) — An expanded recall of ibuprofen oral suspension drops that may contain higher-than-specified levels of ibuprofen that could harm infants’ kidneys has been announced by Tris Pharma, Inc.
More Severe Injuries Sustained at Jump Parks Versus Home Trampolines
WEDNESDAY, Jan. 30, 2019 (HealthDay News) — The proportion of fractures/dislocations, lower-extremity fractures, fractures in adults, and surgical interventions is higher for injuries associated with jump parks versus home trampolines, according to a study published in the Jan. 1 issue of the Journal of the American Academy of Orthopaedic Surgeons.
No Asthma Benefit Seen With n3PUFA in Overweight Teens
WEDNESDAY, Jan. 30, 2019 (HealthDay News) — Omega-3 fatty acid (n3PUFA) supplements do not appear to improve asthma control in teens and young adults who are overweight or obese, according to a study published online Jan. 25 in the Annals of the American Thoracic Society.
1976 to 2016 Saw Drop in Firearm Ownership in Families